| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 143.82 | 8.6% | 32.2% |
| Total Income | 143.82 | 8.6% | 32.2% |
| Expenditure | 120.52 | 0.2% | 15.0% |
| PBT | 23.03 | 36.4% | 441.9% |
| Net Profit | 24.32 | 30.3% | 476.3% |
| OPM | 16.20% | 7.04pp | 12.59pp |
| NPM | 16.91% | 5.27pp | 13.03pp |
| EPS | 0.71 | 31.1% | 446.1% |
TransMedics Reports Q3 2025 Revenue $143.8 Million, Up 32% YoY
04 May 2026 · 4 May, 8:36 am
Summary
TransMedics Group, Inc. reported a 32% increase in revenue for the third quarter of 2025, reaching $143.8 million compared to $108.8 million in the same period of 2024. Net income for the quarter was $24.3 million, or $0.66 per diluted share, a significant increase from $4.2 million in the third quarter of 2024. The company's gross margin improved to 59% from 56% year-over-year. TransMedics is raising its full year 2025 revenue guidance to $595 million to $605 million, representing 36% growth at the midpoint.
Key Highlights
- 1
TransMedics reported total revenue of $143.8 million in the third quarter of 2025, representing a 32% increase compared to the third quarter of 2024.
- 2
The company generated net income of $24.3 million, or $0.66 per diluted share, in the third quarter of 2025.
- 3
Gross margin for the third quarter of 2025 was 59%, compared to 56% in the third quarter of 2024.
- 4
TransMedics is raising its full year 2025 revenue guidance to $595 million to $605 million, representing 36% growth at the midpoint compared to the prior year.
- 5
As of September 30, 2025, TransMedics owned 21 aircraft, and by October 29, 2025, the company owned 22 aircraft.
- 6
A strategic collaboration with Mercedes-Benz Group AG was announced to deploy a fleet of Mercedes-Benz V-Class vehicles for organ transportation across Italy.
Management Comments
Waleed Hassanein
M.D.
Overall, we are very pleased with our third quarter performance and the significant progress our team is making across multiple growth initiatives in the U.S. and globally. Importantly, we are now laser focused on ending 2025 on a strong note while creating the foundation for another strong growth year in 2026. TransMedics is uniquely positioned with our unparalleled OCSTM technology, first-of-their-kind NOPTM clinical and logistical networks, and proprietary NOP ConnectTM digital ecosystem, which collectively enable us to deliver unrivalled lifesaving solutions to transplant markets worldwide. These fundamental advantages set us up well to achieve and likely surpass our target of performing 10,000 U.S. NOP transplants in 2028.
Informational and educational content only. Not investment advice.